A5016564010- Receptor Mechanisms and Signaling
- Neuropeptides and Animal Physiology
- Pharmacological Effects and Assays
- Diet and metabolism studies
- Asthma and respiratory diseases
- Pancreatic function and diabetes
- Mast cells and histamine
- Gastrointestinal motility and disorders
- Adenosine and Purinergic Signaling
- X-ray Diffraction in Crystallography
- Biochemical Analysis and Sensing Techniques
- Crystallization and Solubility Studies
- Urinary Bladder and Prostate Research
- Mass Spectrometry Techniques and Applications
- Ion Channels and Receptors
- Chemokine receptors and signaling
- Food Allergy and Anaphylaxis Research
- Chemical Synthesis and Analysis
- Neuroendocrine regulation and behavior
- Sphingolipid Metabolism and Signaling
- Diabetes Treatment and Management
- Diagnosis and Treatment of Venous Diseases
- Cancer, Stress, Anesthesia, and Immune Response
- Cannabis and Cannabinoid Research
- Olfactory and Sensory Function Studies
University of Glasgow
2019-2023
Jena University Hospital
2023
Technical University of Munich
2016-2018
Volatile small molecules, including the short-chain fatty acids (SCFAs), acetate and propionate, released by gut microbiota from catabolism of nondigestible starches, can act in a hormone-like fashion via specific G-protein-coupled receptors (GPCRs). The primary GPCR targets for these SCFAs are FFA2 FFA3. Using transgenic mice which was replaced an altered form called Designer Receptor Exclusively Activated Drugs (FFA2-DREADD), but FFA3 is unaltered, newly identified FFA2-DREADD agonist...
Introduction: It is suggested that an altered microenvironment in the gut wall alters communication along a mast cell nerve axis. We aimed to record for first time signaling between cells and neurons intact human submucous preparations. Methods: used Ca2+ sensitive dye Fluo-4 AM simultaneously image changes intracellular calcium [Ca+2]i (%ΔF/F) cells. Data are presented as median with interquartile ranges (25/75%). Results: recorded responses 29 samples upon selective activation of 223 by...
Free fatty acid receptor 3 (FFA3, previously GPR41) is activated by short-chain acids, mediates health effects of the gut microbiota, and a therapeutic target for metabolic inflammatory diseases. The shortage well-characterized tool compounds has however impeded progress. Herein, we report structure–activity relationship an allosteric modulator series characterization physicochemical pharmacokinetic properties selected compounds, including previous new tools. Two representatives, 57...
Free fatty acid receptor 2 (FFAR2) is activated by short-chain acids and expressed widely, including in white adipocytes various immune enteroendocrine cells. Using both wild-type human FFAR2 a designer exclusively drug (DREADD) variant we explored the activation phosphorylation profile of receptor, heterologous cell lines tissues from transgenic knock-in mouse expressing either or FFAR2-DREADD. phospho-site-specific antisera targeting pSer 296 /pSer 297 pThr 306 /pThr 310 provided sensitive...
Abstract The gut-brain axis allows bi-directional communication between the enteric and central nervous systems. Short chain fatty acids (SCFAs) generated by gut microbiota are important regulators of this interface. However, defining mechanisms which SCFAs do so has been challenging because, amongst various roles, they co-activate both a pair closely related poorly characterized G protein-coupled receptors, FFA2 FFA3. Designer Receptors Exclusively Activated Drugs (DREADDs) can provide an...
<h3>Introduction</h3> Short chain fatty acids are produced mainly by the gut microbiota. They mediate a variety of biological effects acting on two G protein-coupled receptors. These receptors expressed various cell types, including in gut. The exact contribution free acid 2 receptor (FFA2) regulating physiology is unclear. Bolognini et al<sup>1</sup>, recently employed novel FFA2-Designer Receptor Exclusively Activated Designer Drugs (DREADD) to study physiological role FFA2. Now we...
Abstract Free Fatty Acid receptor 2 (FFA2) is activated by short-chain fatty acids and expressed widely, including in white adipocytes various immune enteroendocrine cells. Using both wild type human FFA2 a Designer Receptor Exclusively Activated Drugs (DREADD) variant we explored the activation phosphorylation profile of receptor, heterologous cell lines tissues from transgenic knock-in mouse expressing either or FFA2-DREADD. phospho-site specific antisera targeting pSer 296 /pSer 297 pThr...
Free Fatty Acid receptor 2 (FFA2) is activated by short-chain fatty acids and expressed widely, including in white adipocytes various immune enteroendocrine cells. Using both wild type human FFA2 a Designer Receptor Exclusively Activated Drugs (DREADD) variant we explored the activation phosphorylation profile of receptor, heterologous cell lines tissues from transgenic knock-in mouse expressing either or FFA2-DREADD. phospho-site specific antisera targeting pSer 296 /pSer 297 pThr 306 /pThr...
Free Fatty Acid receptor 2 (FFA2) is activated by short-chain fatty acids and expressed widely, including in white adipocytes various immune enteroendocrine cells. Using both wild type human FFA2 a Designer Receptor Exclusively Activated Drugs (DREADD) variant we explored the activation phosphorylation profile of receptor, heterologous cell lines tissues from transgenic knock-in mouse expressing either or FFA2-DREADD. phospho-site specific antisera targeting pSer 296 /pSer 297 pThr 306 /pThr...
Free fatty acid receptor 2 (FFAR2) is activated by short-chain acids and expressed widely, including in white adipocytes various immune enteroendocrine cells. Using both wild-type human FFAR2 a designer exclusively drug (DREADD) variant we explored the activation phosphorylation profile of receptor, heterologous cell lines tissues from transgenic knock-in mouse expressing either or FFAR2-DREADD. phospho-site-specific antisera targeting pSer 296 /pSer 297 pThr 306 /pThr 310 provided sensitive...